Prostaglandin E1 and Survival in Patients with the Adult Respiratory Distress Syndrome: A Prospective Trial
Prostaglandin E1 and Survival in Patients with the Adult Respiratory Distress Syndrome: A Prospective Trial
复制标题
前列腺素 E1 与成人呼吸窘迫综合征患者的生存：一项前瞻性试验
DOI：
10.1097/00000658-198604000-00006
复制
发表时间：
1986
影响因子：
9
通讯作者：
C. J. Weber
中科院分区：
文献类型：
--
作者：
J. Holcroft;M. Vassar;C. J. Weber
在一项前瞻性、随机、安慰剂对照、双盲试验中，对患有成人呼吸窘迫综合征 (ARDS) 的手术患者进行为期 7 天的免疫调节剂前列腺素 E1 (PGE1) 输注进行了评估。该药物似乎可以改善肺功能——与 9 名安慰剂患者相比，只有 2 名 PGE1 患者死于严重肺功能衰竭 (p = 0.01)。输注结束后 30 天（研究的预定终点）的存活率在接受 PGE1 的患者中显着提高 (p = 0.03)，21 名 PGE1 患者中有 15 名 (71%) 此时存活，而 20 名安慰剂患者中有 7 名 (35%) 存活。在 PGE 患者的总生存率改善方面，患者并未达到统计学显着性（p = 0.08）。然而，最初没有严重器官衰竭的患者的总生存期在 PGE 患者中明显更好（p = 0.03）。入院时未出现严重器官衰竭的 6 名 PGE1 患者中，全部存活并出院； 10 名安慰剂患者最初没有严重器官衰竭，其中 4 人幸存。该药物没有严重的副作用，也不会增加对感染的易感性。 PGE1 是治疗 ARDS 的有前途的药物。
A 7-day infusion of prostaglandin E1 (PGE1), an immunomodulator, was evaluated in a prospective, randomized, placebo-controlled, double-blinded trial in surgical patients with the adult respiratory distress syndrome (ARDS). The drug seemed to improve pulmonary function—only two PGE1 patients died with severe pulmonary failure compared with nine placebo patients (p = 0.01). Survival at 30 days after the end of the infusion— the predetermined end point of the study—was significantly better in the patients given PGE1 (p = 0.03), with 15 of 21 PGE1 patients (71%) alive at this time compared with seven of 20 placebo patients (35%). Improvement in overall survival in the PGE, patients did not reach statistical significance (p = 0.08). Overall survival in patients initially free of severe organ failure, however, was significantly better in the PGE, patients (p = 0.03). Of the six PGE1 patients free of severe organ failure at time of entry, all survived to leave the hospital; of the 10 placebo patients initially free of severe organ failure, four survived. The drug had no serious side effects and did not potentiate susceptibility to infection. PGE1 is a promising agent for the treatment of ARDS.